Figure 3.
Combined impact of peripheral blood MS and BM MRD on PFS. Comparison of PFS in landmark analysis after cycle 18 between those who were double negative (BM and peripheral blood) and those negative in 1 but positive in the other modality. (A) MS and MFC and (B) MS and NGS at the 10–5 threshold.